30
Participants
Start Date
July 9, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
Dexpramipexole Dihydrochloride
Administration of dexpramipexole tablet
Research Site US-10001-002, DuBois
Research Site US-10001-013, Philadelphia
Research Site US-10001-020, Baltimore
Research Site US-10001-007, Gastonia
Research US-10001-010, Charlotte
Research Site US-10001-025, Charlotte
Research Site US-10001-012, Rock Hill
Research Site US-10001-030, Orlando
Research Site US-10001-004, Columbus
Research Site US-10001-021, Hammond
Research Site US-10001-024, Farmington Hills
Research Site US-10001-033, Des Moines
Research Site 10001-032, Champaign
Research Site US-10001-001, St Louis
Research Site US-10001-005, Saint Charles
Research Site US-10001-017, Conway
Research Site 10001-026, McKinney
Research Site US-10001-009, Corsicana
Research Site US-10001-038, Houston
Research Site US-10001-022, Northridge
Research Site US-10001-008, Newport Beach
Research Site US-10001-016, Westminster
Research Site US-10001-023, East Providence
Lead Sponsor
Areteia Therapeutics
INDUSTRY